vs
Aclarion, Inc.（ACON）与BIODESIX INC（BDSX）财务数据对比。点击上方公司名可切换其他公司
BIODESIX INC的季度营收约是Aclarion, Inc.的1556.2倍（$28.8M vs $18.5K）。BIODESIX INC净利率更高（-13.8% vs -10223.7%，领先10209.9%）。Aclarion, Inc.同比增速更快（80.6% vs 40.8%）。过去两年BIODESIX INC的营收复合增速更高（39.3% vs 35.2%）
Aclarion, Inc.是一家专注于慢性下背痛诊疗的医疗科技企业，核心产品基于专利磁共振波谱技术，可精准识别患者的疼痛性椎间盘，服务美国市场的医疗机构与患者，业务覆盖慢性疼痛管理、脊柱护理两大核心领域。
BIODESIX INC是一家专注于肿瘤与感染病领域的分子诊断企业，开发并商业化创新血液检测解决方案，主要服务北美地区的医疗机构、生物制药合作伙伴及患者，核心业务包括辅助临床决策的个性化医疗产品。
ACON vs BDSX — 直观对比
营收规模更大
BDSX
是对方的1556.2倍
$18.5K
营收增速更快
ACON
高出39.8%
40.8%
净利率更高
BDSX
高出10209.9%
-10223.7%
两年增速更快
BDSX
近两年复合增速
35.2%
损益表 — Q4 2025 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $18.5K | $28.8M |
| 净利润 | $-1.9M | $-4.0M |
| 毛利率 | 9.7% | — |
| 营业利润率 | -10785.8% | -6.8% |
| 净利率 | -10223.7% | -13.8% |
| 营收同比 | 80.6% | 40.8% |
| 净利润同比 | 5.0% | 51.8% |
| 每股收益（稀释后） | $1.39 | $-3.35 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ACONBDSX
| Q4 25 | $18.5K | $28.8M | ||
| Q3 25 | $18.9K | $21.8M | ||
| Q2 25 | $19.3K | $20.0M | ||
| Q1 25 | $19.0K | $18.0M | ||
| Q4 24 | $10.2K | $20.4M | ||
| Q3 24 | $14.4K | $18.2M | ||
| Q2 24 | $11.0K | $17.9M | ||
| Q1 24 | $10.1K | $14.8M |
净利润ACONBDSX
| Q4 25 | $-1.9M | $-4.0M | ||
| Q3 25 | $-1.7M | $-8.7M | ||
| Q2 25 | $-1.6M | $-11.5M | ||
| Q1 25 | $-2.0M | $-11.1M | ||
| Q4 24 | $-2.0M | $-8.3M | ||
| Q3 24 | $-1.4M | $-10.3M | ||
| Q2 24 | $-1.2M | $-10.8M | ||
| Q1 24 | $-2.4M | $-13.6M |
毛利率ACONBDSX
| Q4 25 | 9.7% | — | ||
| Q3 25 | 23.2% | — | ||
| Q2 25 | 26.6% | — | ||
| Q1 25 | -23.6% | — | ||
| Q4 24 | -100.9% | — | ||
| Q3 24 | -48.1% | — | ||
| Q2 24 | -112.3% | — | ||
| Q1 24 | -92.6% | — |
营业利润率ACONBDSX
| Q4 25 | -10785.8% | -6.8% | ||
| Q3 25 | -9666.2% | -32.4% | ||
| Q2 25 | -8988.6% | -48.6% | ||
| Q1 25 | -7856.0% | -50.9% | ||
| Q4 24 | -17652.7% | -32.5% | ||
| Q3 24 | -8995.3% | -47.3% | ||
| Q2 24 | -10350.6% | -46.0% | ||
| Q1 24 | -12609.3% | -74.4% |
净利率ACONBDSX
| Q4 25 | -10223.7% | -13.8% | ||
| Q3 25 | -9008.0% | -40.0% | ||
| Q2 25 | -8285.9% | -57.3% | ||
| Q1 25 | -10728.4% | -61.8% | ||
| Q4 24 | -19444.6% | -40.4% | ||
| Q3 24 | -9482.7% | -56.5% | ||
| Q2 24 | -11285.0% | -60.3% | ||
| Q1 24 | -23720.6% | -91.9% |
每股收益（稀释后）ACONBDSX
| Q4 25 | $1.39 | $-3.35 | ||
| Q3 25 | $-2.93 | $-1.16 | ||
| Q2 25 | $-2.75 | $-0.08 | ||
| Q1 25 | $-9.32 | $-0.08 | ||
| Q4 24 | $-809.36 | $-5.02 | ||
| Q3 24 | $-1321.49 | $-1.40 | ||
| Q2 24 | $-1362.83 | $-0.08 | ||
| Q1 24 | $-3985.22 | $-0.14 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $12.0M | $19.0M |
| 总债务越低越好 | — | $50.0M |
| 股东权益账面价值 | $12.8M | $-2.5M |
| 总资产 | $13.7M | $87.5M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资ACONBDSX
| Q4 25 | $12.0M | $19.0M | ||
| Q3 25 | $11.3M | $16.6M | ||
| Q2 25 | $12.8M | $20.7M | ||
| Q1 25 | $14.8M | $17.6M | ||
| Q4 24 | $453.7K | $26.2M | ||
| Q3 24 | $1.3M | $31.4M | ||
| Q2 24 | $1.2M | $42.2M | ||
| Q1 24 | $2.1M | $11.5M |
总债务ACONBDSX
| Q4 25 | — | $50.0M | ||
| Q3 25 | — | $50.0M | ||
| Q2 25 | — | $50.0M | ||
| Q1 25 | — | $40.0M | ||
| Q4 24 | — | $40.0M | ||
| Q3 24 | — | $40.0M | ||
| Q2 24 | — | $40.1M | ||
| Q1 24 | — | $40.1M |
股东权益ACONBDSX
| Q4 25 | $12.8M | $-2.5M | ||
| Q3 25 | $12.5M | $-1.7M | ||
| Q2 25 | $14.2M | $1.1M | ||
| Q1 25 | $15.8M | $11.1M | ||
| Q4 24 | $970.1K | $20.9M | ||
| Q3 24 | $2.5M | $27.9M | ||
| Q2 24 | $1.6M | $36.3M | ||
| Q1 24 | $2.5M | $-5.5M |
总资产ACONBDSX
| Q4 25 | $13.7M | $87.5M | ||
| Q3 25 | $13.2M | $88.7M | ||
| Q2 25 | $14.8M | $87.7M | ||
| Q1 25 | $16.5M | $86.2M | ||
| Q4 24 | $2.1M | $97.2M | ||
| Q3 24 | $3.2M | $102.7M | ||
| Q2 24 | $3.1M | $115.8M | ||
| Q1 24 | $3.7M | $87.2M |
负债/权益比ACONBDSX
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | 43.95× | ||
| Q1 25 | — | 3.62× | ||
| Q4 24 | — | 1.92× | ||
| Q3 24 | — | 1.44× | ||
| Q2 24 | — | 1.10× | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-1.6M | $778.0K |
| 自由现金流经营现金流 - 资本支出 | — | $692.0K |
| 自由现金流率自由现金流/营收 | — | 2.4% |
| 资本支出强度资本支出/营收 | — | 0.3% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | $-23.5M |
8季度趋势，按日历期对齐
经营现金流ACONBDSX
| Q4 25 | $-1.6M | $778.0K | ||
| Q3 25 | $-1.2M | $-8.9M | ||
| Q2 25 | $-1.9M | $-6.6M | ||
| Q1 25 | $-2.5M | $-8.6M | ||
| Q4 24 | $-922.9K | $-4.1M | ||
| Q3 24 | $-1.1M | $-10.7M | ||
| Q2 24 | $-1.1M | $-18.6M | ||
| Q1 24 | $-2.2M | $-15.3M |
自由现金流ACONBDSX
| Q4 25 | — | $692.0K | ||
| Q3 25 | $-1.2M | $-8.9M | ||
| Q2 25 | — | $-6.6M | ||
| Q1 25 | — | $-8.7M | ||
| Q4 24 | — | $-4.9M | ||
| Q3 24 | — | $-10.9M | ||
| Q2 24 | — | $-20.5M | ||
| Q1 24 | — | $-15.5M |
自由现金流率ACONBDSX
| Q4 25 | — | 2.4% | ||
| Q3 25 | -6164.6% | -41.0% | ||
| Q2 25 | — | -33.1% | ||
| Q1 25 | — | -48.3% | ||
| Q4 24 | — | -24.2% | ||
| Q3 24 | — | -60.1% | ||
| Q2 24 | — | -114.3% | ||
| Q1 24 | — | -104.9% |
资本支出强度ACONBDSX
| Q4 25 | — | 0.3% | ||
| Q3 25 | 38.6% | 0.2% | ||
| Q2 25 | — | 0.3% | ||
| Q1 25 | — | 0.4% | ||
| Q4 24 | — | 4.1% | ||
| Q3 24 | 0.0% | 1.3% | ||
| Q2 24 | — | 10.7% | ||
| Q1 24 | — | 1.6% |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ACON
暂无分部数据
BDSX
| Diagnostic Tests | $25.1M | 87% |
| Development Services | $3.6M | 13% |
